Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 1038-1047

  Gore, M E ^a   Bellmunt, J ^b   Eisen, T ^c   Escudier, B ^d   Mickisch, G ^e   Patard, J ^f   Porta, C ^g   Ravaud, A ^h   Schmidinger, M ⁱ   Schoffski P ^j   Sternberg, C N ^k   Szczylik, C ^l   De Nigris, E ^m   Wheeler, C ^m   Kirpekar, S ^m  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

^c St John's Innovation Centre   (United Kingdom)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Center of Operative Urology Bremen (COUB)   (Germany)

^f BICÊTRE HOSPITAL   (France)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h HÔPITAL SAINT ANDRÉ   (France)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l MILITARY INSTITUTE OF MEDICINE   (Poland)

^m Double Helix Consulting   (United Kingdom)

more..

Author keywords

Expert opinion; RAND UCLA methodology; Renal cell carcinoma; Treatment guidelines

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ALGORITHM; CANCER THERAPY; EVALUATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VALIDATION STUDY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; EVIDENCE-BASED MEDICINE; EXPERT SYSTEMS; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY; TREATMENT OUTCOME;

EID: 84859515530     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.058     Document Type: Article

References (73)

1. B.I. Rini Metastatic renal cell carcinoma: many treatment options, one patient J Clin Oncol 27 2009 3225 3234
2. B. Escudier, and V. Kataja Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 2009 81 82
3. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
4. R.J. Halbert, R.A. Figlin, and M.B. Atkins Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel Cancer 107 2006 Nov 2375 2383
5. Fitch K, et al. The RAND/UCLA Appropriateness Method User's Manual. Rand Corporation, 2001.
6. K.Y. Bilimoria, M.V. Raval, and D.J. Bentrem National assessment of melanoma care using formally developed quality indicators J Clin Oncol 27 2009 5445 5451
7. D.C. Hodgson, J.D. Brierley, and G. Cernat The consistency of panelists' appropriateness ratings: do experts produce clinically logical scores for rectal cancer treatment? Health Policy 71 2005 57 65
8. M.L. McGory, P.G. Shekelle, and C.Y. Ko Development of quality indicators for patients undergoing colorectal cancer surgery J Natl Cancer Inst 98 2006 1623 1633
9. K.Y. Bilimoria, D.J. Bentrem, K.D. Lillemoe, M.S. Talamonti, and C.Y. Ko Assessment of pancreatic cancer care in the United States based on formally developed quality indicators J Natl Cancer Inst 101 2009 848 859
10. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
11. D.A. Karnofsky, and J.H. Burchenal The clinical evaluation of chemotherapeutic agents in cancer C.M. MacLeod, Evaluation of chemotherapeutic agents 1949 Columbia University Press New York 191 205
12. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
13. D.R. Feldman, M.S. Baum, and M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
14. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
15. M. Johannsen, A. Florcken, and A. Bex Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis Eur Urol 55 2009 1430 1438
16. L.F. Kontovinis, K.T. Papazisis, and P. Touplikioti Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers BMC Cancer 9 2009 82
17. R.J. Motzer, M.D. Michaelson, and J. Rosenberg Sunitinib efficacy against advanced renal cell carcinoma J Urol 178 2007 1883 1887
18. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
19. A. Polyzos Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors J Steroid Biochem Mol Biol 108 2008 261 266
20. H. Uemura, N. Shinohara, and T. Yuasa A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety Jpn J Clin Oncol 40 2010 194 202
21. H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Jpn J Clin Oncol 37 2007 755 762
22. L.G. Di, G. Carteni, and R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
23. T. Eisen, S. Oudard, and C. Szczylik Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial J Natl Cancer Inst 100 2008 1454 1463
24. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
25. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
26. J.A. Gollob, W.K. Rathmell, and T.M. Richmond Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 2007 3288 3295
27. E. Jonasch, P. Corn, and L.C. Pagliaro Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis Cancer 116 2010 57 65
28. D.A. Laber, and M. Mushtaq Compassionate use of sorafenib in patients with advanced renal cell cancer Clin Genitourin Cancer 7 2009 34 38
29. H. Zhang, B. Dong, and J.J. Lu Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study BMC Cancer 9 2009 249
30. J. Bellmunt, J.M. Trigo, and E. Calvo Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06) Lancet Oncol 11 2010 350 357
31. C.W. Ryan, B.H. Goldman, and P.N. Lara Jr Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 2007 3296 3301
32. M.J. Ratain, T. Eisen, and W.M. Stadler Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512
33. R.M. Bukowski, F.F. Kabbinavar, and R.A. Figlin Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer J Clin Oncol 25 2007 4536 4541
34. B. Escudier, J. Bellmunt, and S. Negrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
35. J.D. Hainsworth, J.A. Sosman, and D.R. Spigel Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib J Clin Oncol 23 2005 7889 7896
36. J.D. Hainsworth, D.R. Spigel, and H.A. Burris III Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
37. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 25 2009 Sep 1 4076 4081
38. B. Melichar, P. Koralewski, and A. Ravaud First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma Ann Oncol 19 2008 1470 1476
39. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
40. J.D. Hainsworth, D.R. Spigel, and J.A. Sosman Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial Clin Genitourin Cancer 5 2007 427 432
41. J.P. Dutcher, S.P. De, and D. McDermott Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Med Oncol 26 2 2009 202 209
42. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
43. T.E. Hutson, I.D. Davis, and J.P. Machiels Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol 28 2010 475 480
44. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
45. G.H. Mickisch, A. Garin, and H. van Poppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alone in metastatic renal-cell carcinoma: a randomized trial Lancet 358 2001 966 970
46. D.R. Feldman, G.V. Kondagunta, and L. Schwartz Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma Clin Genitourin Cancer 6 2008 25 30
47. M.E. Gore, C.L. Griffin, and B. Hancock Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial Lancet 375 2010 641 648
48. D. Lyrdal, U. Stierner, and S. Lundstam Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b Acta Oncol 48 2009 901 908
49. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
50. R.J. Motzer, B.A. Murphy, and J. Bacik Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 18 2000 2972 2980
51. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
52. G.C. Jayson, M. Middleton, S.M. Lee, L. Ashcroft, and N. Thatcher A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer Br J Cancer 78 1998 366 369
53. E. Esteban-Gonzalez, J. Carballido, and V. Navas Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 Anticancer Drugs 18 2007 291 296
54. T. Klatte, A. Ittenson, and F.W. Rohl Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial Br J Cancer 95 2006 1167 1173
55. G. Messina, P. Lissoni, and E. Bartolacelli Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test Anticancer Res 27 2007 2985 2988
56. J.C. Yang, S.L. Topalian, and D.J. Schwartzentruber The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2 Cancer 76 1995 687 694
57. J.C. Yang, R.M. Sherry, and S.M. Steinberg Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 2003 3127 3132
58. J.I. Clark, M.B. Atkins, and W.J. Urba Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial J Clin Oncol 21 2003 3133 3140
59. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141
60. U. Capitanio, P. Perrotte, and L. Zini Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma) BJU Int 104 2009 795 799
61. R.H. Thompson, S. Siddiqui, and C.M. Lohse Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors J Urol 182 2009 2601 2606
62. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
63. C. Porta, J. Bellmunt, and T. Eisen Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma Cancer Treat Rev 36 2010 16 23
64. R. Passalacqua, C. Buzio, and S. Buti Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer Cancer Immunol Immunother 59 2010 553 561
65. A. Vaglio, F. Alberici, and U. Maggiore Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile Oncology 76 2009 69 76
66. M.E. Gore, C.L. Griffin, and B. Hancock Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial Lancet 375 2010 641 648
67. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
68. T.E. Rix, and T. Bates Pre-operative risk scores for the prediction of outcome in elderly people who require emergency surgery World J Emerg Surg 2 2007 16
69. Sobin LE, Gospodarowicz MK, Wittekind C. TNM classification of Malignant Tumours, 7th Edition; UICC, 2010.
70. R.J. Amato, J. Jac, and S. Giessinger A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer Cancer 115 2009 2438 2446
71. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-7896.
72. Hainsworth JD, Spigel DR, Burris HA, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28:2131-2136.
73. R.J. Motzer, B. Escudier, S. Oudard RECORD-1 Study Group Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265